Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B

  1. Pieter A Roelofs
  2. Chai Yeen Goh
  3. Boon Haow Chua
  4. Matthew C Jarvis
  5. Teneale A Stewart
  6. Jennifer L McCann
  7. Rebecca M McDougle
  8. Michael A Carpenter
  9. John WM Martens
  10. Paul N Span
  11. Dennis Kappei
  12. Reuben S Harris  Is a corresponding author
  1. University of Minnesota, United States
  2. National University of Singapore, Singapore
  3. Howard Hughes Medical Institute, University of Minnesota, United States
  4. Erasmus MC Cancer Institute, Erasmus University Medical Center, Netherlands
  5. Radboud University Medical Center, Netherlands [NL]

Abstract

APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here, we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution.

Data availability

Raw mass spectrometry data will be accessible through the ProteomeXchange Consortium via the PRIDE (Vizcaino et al., 2016) partner repository with the dataset identifier PXD020473. Additional data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Pieter A Roelofs

    Biochemistry, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  2. Chai Yeen Goh

    Translational Medicine, National University of Singapore, Singapore, Singapore
    Competing interests
    No competing interests declared.
  3. Boon Haow Chua

    Translational Medicine, National University of Singapore, Singapore, Singapore
    Competing interests
    No competing interests declared.
  4. Matthew C Jarvis

    Microbiology and Immunology, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  5. Teneale A Stewart

    Biochemistry, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  6. Jennifer L McCann

    Microbiology and Immunology, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0458-1335
  7. Rebecca M McDougle

    Biochemistry, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  8. Michael A Carpenter

    Biochemistry, Howard Hughes Medical Institute, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  9. John WM Martens

    Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands
    Competing interests
    No competing interests declared.
  10. Paul N Span

    Radboud University Medical Center, Nijmegen, Netherlands [NL]
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1930-6638
  11. Dennis Kappei

    Translational Medicine, National University of Singapore, Singapore, Singapore
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3582-2253
  12. Reuben S Harris

    Biochemistry, Howard Hughes Medical Institute, University of Minnesota, Minneapolis, United States
    For correspondence
    rsh@umn.edu
    Competing interests
    Reuben S Harris, RSH is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9034-9112

Funding

National Cancer Institute (P01-CA234228)

  • Reuben S Harris

KWF Kankerbestrijding (KWF10270)

  • John WM Martens
  • Paul N Span
  • Reuben S Harris

National Research Foundation Singapore (NMRC/OFYIRG/055/2017)

  • Dennis Kappei

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Roelofs et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,005
    views
  • 342
    downloads
  • 29
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Pieter A Roelofs
  2. Chai Yeen Goh
  3. Boon Haow Chua
  4. Matthew C Jarvis
  5. Teneale A Stewart
  6. Jennifer L McCann
  7. Rebecca M McDougle
  8. Michael A Carpenter
  9. John WM Martens
  10. Paul N Span
  11. Dennis Kappei
  12. Reuben S Harris
(2020)
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
eLife 9:e61287.
https://doi.org/10.7554/eLife.61287

Share this article

https://doi.org/10.7554/eLife.61287

Further reading

    1. Cancer Biology
    Qianqian Ju, Wenjing Sheng ... Cheng Sun
    Research Article

    TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.

    1. Cancer Biology
    2. Cell Biology
    Rui Hua, Jean X Jiang
    Insight

    Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.